Efficient and targeted product development for quality assurance of biological drugs

Important results from the project

Antibody-based molecules have enabled new treatments for cancer and infectious diseases and are a strongly growing market. To ensure the quality of these drugs, LC-MS is often used, which requires enzymes in the sample preparation for improved resolution in the analysis. Genovis is a major player in the development of such enzymes, and in this project we have developed a new platform for targeted production of new, effective enzymes to facilitate quality assurance of various biopharmaceuticals.

Expected long term effects

The new technology platform enables a higher capacity to identify new product candidates and thus meet the market´s growing needs. We therefore see that access to this technology will improve our opportunities to continue to position ourselves as a strong player in the global biopharma market. The project also identified, developed and launched a unique, customer-requested, enzyme for use in analytics for quality assurance of biopharmaceuticals.

Approach and implementation

The project was carried out in collaboration with Lund University of Technology and Lund University, where the majority of the platform was developed. The interaction between knowledge-driven academia and market- and application-driven industry was very efficient and created good synergy for innovation. The interaction has been very rewarding and further collaboration between the parties will continue.